Results 111 to 120 of about 37,893 (278)
MedComm, Volume 7, Issue 2, February 2026.Neurons, immune cells, and other cellular components within the disease microenvironment (such as stromal cells and tumor cells) constitute a dynamically evolving ecosystem. Neurons directly modulate immune cell activity and inflammatory responses through the release of neurotransmitters (e.g., norepinephrine and CGRP), while also promoting tumor ...
Xin Guo +11 more
wiley +1 more source
Progress in RNA‐Targeted Therapeutics for Human Diseases
MedComm, Volume 7, Issue 2, February 2026.RNA‐targeted therapies are revolutionizing molecular medicine by transitioning from a “protein‐centric” focus to an “RNA‐regulatory network” approach. Leveraging RNA's diverse roles in gene regulation, signaling, and epigenetic modifications, advanced platforms such as ASOs, siRNA, miRNA, mRNA, aptamers, shRNA, and CRISPR/Cas systems are enabling ...
Wangzheqi Zhang +10 more
wiley +1 more source
Hydrogels for Cancer Immunotherapy: Strategies From Construction to Application
MedComm, Volume 7, Issue 2, February 2026.Hydrogels offer an innovative platform for cancer immunotherapy. Through tailorable crosslinking strategies, they form customizable drug delivery platforms that address diverse therapeutic requirements by loading specific immunotherapeutic agents. These systems demonstrate significant clinical potential for precise tumor immunotherapy.
Xiaohua Chen +8 more
wiley +1 more source
Advances in Therapeutic Antibody Discovery and Development Targeting G Protein‐Coupled Receptors
Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.ABSTRACT G protein‐coupled receptors (GPCRs) are integral to numerous biological processes and are associated with various diseases across all therapeutic areas. Consequently, GPCRs present substantial potential for antibody‐based therapies. This review offers an overview of the therapeutic GPCR‐antibody target landscape and examines the diversity ...
Catherine J. Hutchings +6 more
wiley +1 more source
Measles virus: Background and oncolytic virotherapy
Biochemistry and Biophysics Reports, 2018 Measles is a highly transmissible disease caused by measles virus and remains a major cause of child mortality in developing countries. Measles virus nucleoprotein (N) encapsidates the RNA genome of the virus for providing protection from host cell endonucleases and for specific recognition of viral RNA as template for transcription and replication ...
Sankhajit Bhattacharjee +1 more
openaire +3 more sources
Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients. [PDF]
, 2019 Neoantigen vaccines involving multi-peptides and poly-epitope-encoding RNA or DNA have undergone early phase clinical testing with modest reported antitumor effects [ 1].
Bouvet, Michael +5 more
core +1 more source
Mathematical Modeling of the Role of Cytokines in Sindbis Virus Treatment of Glioblastoma
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.ABSTRACT Oncolytic viruses, specifically Sindbis virus (SINV), combined with cytokines show promising results in slowing glioma progression, but a quantitative understanding of their effects remains limited. In this study, we use an ordinary differential equation (ODE) model to examine the effect of adding cytokines to oncolytic SINV therapy.
Shriya Makam, Hana M. Dobrovolny
wiley +1 more source
Bladder Cancer, 2015 Purpose: Despite recent improvements, resistance to traditional immunotherapy or chemotherapy is still common in patients with bladder cancer. We constructed an oncolytic virus from herpes simplex virus type II (HSV-2), which selectively targets tumor ...
Kwan Joong Joo +3 more
doaj +1 more source